

Appendix Table F31. Improvement in incontinence after topical estrogen treatment compared to no active treatment (individual RCTs)

Reference N	Active	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Holtedahl, 1998 ³⁰⁸ 80	Local estrogen in tablets or jelly	Number of improved: reduction in frequency amount, or wet episodes	36/44	14/39	4/9	4.28 (1.54; 11.87)	0.30 (0.12; 0.48)	3 (2; 9)	298 (117; 478)
Dessole, 2004 ²⁷² 88	Intravaginal estriol ovules: 1 ovule (1 mg) once daily for 2 weeks and then 2 ovules once weekly for 6 months.	Rate of cured and improved	44/44	30/68	7/16	4.29 (2.11; 8.71)	0.52 (0.35; 0.70)	2 (1; 3)	523 (348; 698)
Waetjen, 2005 ³⁹⁹ 417	14 mg of transdermal E2 per day for 4 months	Improved incontinence: the number of incontinence episodes per week decreased by 2 or more, 4 months	208/209	52/25	74/35	0.71 (0.52; 0.95)	-0.10 (-0.19; -0.02)		
Waetjen, 2005 ³⁹⁹ 417	14 mg of transdermal E2 per day for 4 months	Improved incontinence: the number of incontinence episodes per week decreased by 2 or more, 2 years	208/209	57/27	80/38	0.72 (0.54; 0.95)	-0.11 (-0.20; -0.02)	-9 (-52; -5)	-109 (-198; -19)

**Appendix Table F31. Improvement in incontinence after topical estrogen treatment compared to no active treatment (individual RCTs)
(continued)**

Reference N	Active	Definition of outcome	Randomized active/ control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Waetjen, 2005 ³⁹⁹ 417	14 mg of transdermal E2 per day for 4 months	Improved stress incontinence: the number of incontinence episodes per week decreased by 2 or more, 4 months	208/209	30/14	57/27	0.53 (0.36; 0.79)	-0.13 (-0.21; -0.05)	-8 (-19; -5)	-128 (-205 ; -52)
Waetjen, 2005 ³⁹⁹ 417	14 mg of transdermal E2 per day for 4 months	Improved stress incontinence: the number of incontinence episodes per week decreased by 2 or more, 2 years	208/209	37/18	61/29	0.61 (0.43; 0.87)	-0.11 (-0.19; -0.03)	-9 (-30; -5)	-114 (-195; -33)
Waetjen, 2005 ³⁹⁹ 417	14 mg of transdermal E2 per day for 4 months	Improved urge incontinence: the number of incontinence episodes per week decreased by 2 or more, 4 months	208/209	25/12	26/13	0.97 (0.58; 1.62)	0.00 (-0.07; 0.06)		
Waetjen, 2005 ³⁹⁹ 417	14 mg of transdermal E2 per day for 4 months	Improved urge incontinence: the number of incontinence episodes per week decreased by 2 or more, 2 years	208/209	27/13	35/17	0.78 (0.49; 1.23)	-0.04 (-0.11; 0.03)		